These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

494 related items for PubMed ID: 28494463

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
    Li Q, Kuang HY, Wu YH, Lu TW, Yi QJ.
    Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P, Coghlan G.
    Drugs; 2008 May; 68(12):1635-45. PubMed ID: 18681488
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy.
    Abston E, Hon S, Lawrence R, Berman J, Govender P, Farber HW.
    Sarcoidosis Vasc Diffuse Lung Dis; 2020 May; 37(2):234-238. PubMed ID: 33093789
    [Abstract] [Full Text] [Related]

  • 31. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
    Vizza CD, Jansa P, Teal S, Dombi T, Zhou D.
    BMC Cardiovasc Disord; 2017 Sep 06; 17(1):239. PubMed ID: 28874133
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
    Sidharta PN, Krähenbühl S, Dingemanse J.
    Expert Opin Drug Metab Toxicol; 2015 Mar 06; 11(3):437-49. PubMed ID: 25604973
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data.
    Dong S, Guo X, Wang H, Sun C.
    Ther Adv Respir Dis; 2024 Mar 06; 18():17534666231223606. PubMed ID: 38179676
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.
    Aversa M, Porter S, Granton J.
    Drug Saf; 2015 May 06; 38(5):419-35. PubMed ID: 25792028
    [Abstract] [Full Text] [Related]

  • 40. Initial dual oral combination therapy in pulmonary arterial hypertension.
    Sitbon O, Sattler C, Bertoletti L, Savale L, Cottin V, Jaïs X, De Groote P, Chaouat A, Chabannes C, Bergot E, Bouvaist H, Dauphin C, Bourdin A, Bauer F, Montani D, Humbert M, Simonneau G.
    Eur Respir J; 2016 Jun 06; 47(6):1727-36. PubMed ID: 26989105
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.